Heron Therapeutics Announces Public Offering of Common Stock
12/04/2017
|
SAN DIEGO--(BUSINESS WIRE)--Dec. 4, 2017--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage
biotechnology company focused on improving the lives of patients by
developing best-in-class treatments to address some of the most
important unmet patient needs, today announced an underwritten public
offering of its common stock. The closing price of Heron Therapeutics,
Inc.’s common stock on December 1, 2017 was $17.25 per share.
Cantor Fitzgerald & Co. is acting as sole book-running manager for the
offering.
Heron Therapeutics, Inc. intends to use the proceeds from the proposed
sale of its shares of common stock for general corporate purposes, which
include, but are not limited to, the continued commercialization and
marketing of SUSTOL®, the commercial launch of CINVANTI™,
funding its ongoing and future clinical trials, including further Phase
2 studies and Phase 3 studies for HTX-011, preclinical development work,
for general and administrative expenses, repayment of a portion of an
outstanding promissory note, or other product development activities.
The offering is being made pursuant to a registration statement that was
filed with the Securities and Exchange Commission and became
automatically effective on July 6, 2017. The securities described above
have not been qualified under any state blue sky laws. This press
release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction. Copies of the final prospectus supplement (when available)
and accompanying prospectus relating to these securities may also be
obtained by sending a request to: Cantor Fitzgerald & Co., Attention:
Capital Markets, 499 Park Avenue, 6th Floor New York, New York 10022;
Email: prospectus@cantor.com.
Forward-Looking Statements
This news release contains “forward-looking statements” as defined by
the Private Securities Litigation Reform Act of 1995. Heron
Therapeutics, Inc. cautions readers that forward-looking statements are
based on management’s expectations and assumptions as of the date of
this news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially, including, but not
limited to, those associated with: its capital position and the
sufficiency of its capital to fund its operations in future periods; its
use of the net proceeds of the proposed public offering; and other risks
and uncertainties identified in its filings with the Securities and
Exchange Commission. Forward-looking statements reflect its analysis
only on their stated date, and Heron Therapeutics, Inc. undertakes no
obligation to update or revise these statements except as may be
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171204006102/en/
Source: Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
Investor Relations Contact:
David
Szekeres, 858-251-4447
Senior Vice President, General Counsel,
Business Development & Corporate Secretary
dszekeres@herontx.com
or
Corporate
Contact:
David Szekeres, 858-251-4447
Senior Vice
President, General Counsel, Business Development & Corporate Secretary
dszekeres@herontx.com